経口糖尿病薬の新展開

出版社： フジメディカル出版
著者：
発行日： 2012-06-01
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784862700407
電子書籍版： 2012-06-01 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,180 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,090 円(税込)

購入する

商品紹介

　インクレチン関連薬の登場により，経口糖尿病薬のラインナップが一層充実した反面，6系統にも及ぶ薬効群の中から最適の薬剤を選び出すことは，より複雑になりました。病態プロファイル・検査値からみた選択は？ 第一選択薬の決め手は？ 最初の薬剤で血糖コントロールが得られない時の次の一手は？ いかにして患者さんごとの最適な薬剤を選ぶかをテーマに，専門医がクリアカットに解説。あなたの糖尿病診療をサポートします。

目次

  • 経口糖尿病薬の新展開

    ―目次―

    1．経口糖尿病薬の選択における基本知識
    　経口血糖降下薬の種類と特性―SU薬からインクレチン薬まで―
    　経口薬選択の指標―患者のプロファイルから何を読み取るか―
    　経口薬の限界―インスリン注射の導入を見誤らない―

    2．薬剤選択の実際
    　病態・検査値からみた薬剤選択―選択基準・処方の実際・注意点
    　経口薬選択の実際
    　合併症を有する患者における薬剤選択と注意点

    3．トピックス
    　SU薬とインクレチン関連薬併用による低血糖
    　α-GI・ビグアナイド薬とインクレチンの併用
    　インスリンからGLP-1受容体作動薬への切り替えによる高血糖
    　チアゾリジン薬と骨折
    　α-グルコシダーゼ阻害薬・グリニド薬による食後高血糖改善と
    　　大血管イベントに関する大規模スタディ
    　高用量メトホルミン
    　インスリンとDPP-4阻害薬の併用

    4．薬剤一覧

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1. 経口糖尿病薬の選択における基本知識

P.19 掲載の参考文献
1) Nauck M et al:Reduced incretin effect in type 2(non-insulin-dependent)diabetes. Diabetologia 29(1):46-52, 1986.
PubMed
2) Drucker DJ, Nauck MA:The incretin system:glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548):1696-1705, 2006.
PubMed
3) Nauck MA et al:Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36 amide)in type 2(non-insulin-dependent)diabetic patients. Diabetologia 36(8):741-744, 1993.
PubMed
4) Ryan GJ et al:Review of the therapeutic uses of liraglutide. Clin Ther 33(7):793-811, 2011.
PubMed
5) Tornehave D et al:Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 56(9):841-851, 2008.
PubMed
6) Heller RS et al:Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46(5):785-791, 1997.
PubMed
7) de Heer J et al:Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin(receptor subtype 2)in the perfused rat pancreas. Diabetologia 51(12):2263-2270, 2008.
 
8) Willms B et al:Gastric emptying, glucose responses, and insulin secretion after a liquid test meal:effects of exogenous glucagon-like peptide-1(GLP-1)-(7-36)amide in type 2(noninsulin-dependent) diabetic patients, J Clin Endocrinol Metab 81(1):327-332, 1996.
PubMed
9) Toft-Nielsen MB et al:Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22(7):1137-1143, 1999.
PubMed
10) Narita T et al:Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 26(2):187-188, 2009.
PubMed
11) Lee A et al:The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4(5):329-335, 2002.
PubMed
12) Musi N et al:Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51(7):2074-2081, 2002.
PubMed
13) Salpeter SR et al:Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev(4):CD002967, 2010.
 
14) Hauner H:The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18(Suppl 2):S10-15, 2002.
 
15) Sharma PK et al:Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol(Oxf)65(6):722-728, 2006.
PubMed
16) Nakatsuji H et al:Three-month treatment with pioglitazone reduces circulating levels of thiobarbituric acid-reacting substances, a marker of reactive oxidative stress, without change in body mass index, in Japanese patients with type 2 diabetes. Atherosclerosis 212(1):243-245, 2010.
PubMed
17) Meigs JB et al:Fasting and postchallenge glycemia and cardiovascular disease risk:the Framingham Offspring Study. Diabetes Care 25(10):1845-1850, 2002.
PubMed
18) DECODE:Glucose tolerance and cardiovascular mortality:comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161(3):397-405, 2001.
PubMed
19) Chiasson JL et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial Lancet 359(9323):2072-2077, 2002.
PubMed
P.23 掲載の参考文献
1) The diabetes control and complications trial (DCCT)research group:The effect of intensive treatment of diabetes on the development and progression on long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-96, 1993
 
2) UK prospective diabetes study(UKPDS)group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352:837-853, 1998
 
3) The DECODE study group, on behalf of the european diabetes epidemiology group:Glucose tolerance and cardiovascular mortality comparison of asting and 2-hour diagnostic criteria. Arch Intern Med 161:397-404, 2001
 
4) Tominaga M et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The fukunaga diabetes study. Diabetes Care 22:920-924, 1999
 
5) ADVANCE collaborative group:Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410-1418, 2010
 
P.28 掲載の参考文献
1) Mcewan et al:The 44th Annial Meeting of the European Association for the Study of Diabetes #152
 
2) 日本糖尿病学会編:糖尿病治療ガイド 2010. 東京, 文光堂, 2010
 
3) 三浦順之助:肝障害を伴う糖尿病の血糖コントロール. 糖尿病診療マスター 3(2):228-229, 2005
 
4) 内潟安子:外来におけるインスリン治療の進め方のコツ. 糖尿病診療マスター 1(3):329-332, 2003
 
5) Tanaka Y et al:Usefulness of revised fasting plasma glucose criterion and characteristics of the insulin resoponse to and oral glucose load in newly Japanese diabetic subjects. Diabetes Care 21:1131-1137, 1998
 
6) 梶本佳孝ほか:糖毒性. 新時代の糖尿病学1. 日本臨床(増刊号) :511-522, 2002
 
7) 内潟安子:糖尿病のインスリン治療は, いつから, どのように, どのくらいから. 糖尿病診療マスター 2(1):21-26, 2004
 
8) Funakoshi S et al:Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation 2:297-303, 2011. DOI:10. 1111/j. 2040-1124, 2010. 00096.
 
9) Maruyama T et al:Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin(The Tokyo Study):preliminary report. Ann N Y Acad Sci 1005:362-369, 2003
PubMed
10) 内潟安子:インスリン導入のタイミング. Mebio 22:5, 2005
Medical*Online

2. 薬剤選択の実際

P.36 掲載の参考文献
1) 日本糖尿病学会編:糖尿病治療ガイド 2010. 東京, 文光堂, 2010
 
2) Gribble FM et al:Tissue specificity of sulfonylurea:studies on cloned cardiac and beta-cell KATp channels. Diabetes 47:1412-1418, 1998
PubMed
3) Monami M et al:Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 22:477-482, 2006
PubMed
4) 日本糖尿病対策推進会議編:糖尿病治療のエッセンス 2010-2011. 東京, 文光堂, 2010
 
5) 日本糖尿病学会編:血糖降下薬による治療(インスリンを除く):科学的根拠に基づく糖尿病診療ガイドライン 2010. 東京, 南江堂, 2010, pp51-63
 
6) United Kingdom Prospective Diabetes Study(UKPDS)Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352:837-853, 1998
 
7) Holman RR et al:10-year follow-up of intensive glucose control in type 2 diabetes(UKPDS 80). N Engl J Med 359:1577-1589, 2008
PubMed
8) The ADVANCE Collaborative Group:Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572, 2008
 
P.49 掲載の参考文献
1) Stratton IM et al:Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes(UKPDS 35):prospective observational study. BMJ 321:405-412, 2000
PubMed
2) 森 豊:持続血糖測定(CGM). 治療 92:569-576, 2010
Medical*Online
3) The Action to Control Cardiovascular Risk in Diabetes Study Group:Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 358:2545-2559, 2008
 
4) Desouza C et. al:Association of hypoglycemia and cardiac ischemia:a study based on continuous monitoring. Diabetes Care 26:1485-1489, 2003
 
5) 森 豊:食後血糖改善薬の特徴と使い方. 月刊糖尿病 4 (5) :58-67, 2012
 
6) 森 豊:よりきめ細かい糖尿病治療を目指して-CGMの応用 1 経口薬処方の見直し. 糖尿病の最新治療 1:31-37, 2009
Medical*Online
7) Mori Y et al:Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia:comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats. Diabetes Obes Metab 6:422-431, 2004
PubMed
8) Mori Y et al:Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. Endocrine 29:309-315, 2006
PubMed
9) Taki H et al:Postmarketing surveillance study of nateglinide in Japan. Adv Ther 22:513-526, 2005
PubMed
10) Taki H et al:Postmarketing study of nateglinide in Japan:treatment of medication-naive patients with type 2 diabetes. Adv Ther 22:621-635, 2005
PubMed
11) Taki H et al:Study of nateglinide in Japan:long-term treatment of patients with type 2 diabetes. Adv Ther 23:307-324, 2006
PubMed
12) 高橋健二ほか:2型糖尿病に対するナテグリニドの有効性に関する分析. 倉敷中病年報 65:25-29, 2002
Medical*Online
13) 大島英二:2型糖尿病患者を対象としたナテグリニド有効症例判定におけるC/G比測定の有用性. Diabetes frontier 15:882-886, 2004
Medical*Online
14) 福田正博ほか:糖尿病診療における1回尿Cペプチド値の有用性-糖尿病治療法選択時の指標としての検討-. 日本臨床内科医会会誌 18:532-538, 2004
Medical*Online
15) 森 豊:CGMの結果から考えられる理想的な経口血糖降下薬の使い方-併用療法の意義. 日本臨床 69:1505-1514, 2011
Medical*Online
16) 森 豊:グリニド薬. 月刊糖尿病 3 (6):52-65, 2011
 
17) 森 豊:インスリン分泌促進系薬剤 (診療controversy--medical decision makingのために 経口糖尿病薬のfirst choice). 内科 104:913-919, 2009
 
18) 森 豊:α-グルコシダーゼ阻害薬. 治療学 44:36-44, 2010
Medical*Online
19) Mori Y et al:Evaluation of efficacy of acarbose on glucose fluctuation and postprandial glucose using continuous glucose monitoring in type 2 diabetes mellitus. Diabetes Technol Ther 13:467-470, 2011
PubMed
20) 森 豊:グリニド系薬剤の機序と効果は? 食後高血糖に対するグリニド系薬剤の機序と効果について教えてください. 肥満と糖尿病 7:856-861, 2008
 
21) 森 豊ほか:自然発症糖尿病OLETFラットにおけるスクロース負荷後の血糖上昇, インスリン分泌動態に及ぼすミチグリニドとボグリボースの併用効果. Ther Res 32:1475-1481, 2011
Medical*Online
P.53 掲載の参考文献
1) Igarashi Y et al:Characteristics of Japanese subjects who progress from normal to impaired glucose tolerance. Longitudinal study excluding changes in body weight. Endocr J 52:683-689, 2005
PubMed
2) Williams SB et al:Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97:1695-1701, 1998
PubMed
3) Kawano H et al:Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146-154, 1999
PubMed
4) DECODE study group:Glucose tolerance and cardiovascular mortality. comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405, 2001
 
5) Tominaga M et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The funagata diabetes study. Diabetes Care 22:920-924, 1999
 
6) Chiasson JL et al:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 290:486-494, 2003
PubMed
7) Hanefeld M et al:Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients. Meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
PubMed
8) van de Lear FA et al:Alpha-glucosidase inhibitors for patients with type 2 diabetes. Results from a Cochrane systematic review and meta-analysis. Diabetes Care 28:154-163, 2005
 
9) Kawamori R et al:Voglibose for prevention of type 2 diabetes mellitus. A randomized, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373:1607-1614, 2009
PubMed
10) Arakawa M et al:Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 57:1299-1306, 2008
PubMed
11) Nemoto M et al:Efficacy of combined use of miglitol in type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study. Acta Diabetol 48:15-20, 2011
PubMed
P.58 掲載の参考文献
1) DeFronzo RA:Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin study group. N Engl J Med 333(9):541-549, 1995
 
2) UK Prospective Diabetes Study(UKPDS)group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet 352(9131):854-865, 1998
PubMed
3) Zhou G et al:Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108(8):1167-1174, 2001
PubMed
4) Ruiter R et al:Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives:Results from a large population-based follow-up study. Diabetes Care 35(1):119-124, 2012
PubMed
5) 加来浩平ほか:2型糖尿病治療におけるメトホルミンの使用実態に関する観察研究 (MORE study). 糖尿病 49(5):325-331, 2006
 
6) Strowig SM et al:Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 25(10):1691-1698, 2002
PubMed
7) Kaku K:Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes:adouble-blind, placebo-controlled, clinical trial. Cur Med Res Opin 25:1111-1119, 2009
 
8) Lindsay JR et al:Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 22(5):654-657, 2005
PubMed
9) Mannucci E et al:Effect of metformin on glucagon-like peptide 1(GLP-1)and leptin levels in obese nondiabetic subjects. Diabetes Care 24(3):489-494, 2001
PubMed
P.64 掲載の参考文献
1) Yki-Jarvinen H et al:Thiazolidinediones. N Engl J Med 351:1106-1118, 2004
PubMed
2) Kubota N et al:Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and independent pathways. J Biol Chem 281:8748-8755, 2006
PubMed
3) Kadowaki T et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
PubMed
4) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
PubMed
5) Erdmann E et al:The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction:results from the PROactive(PROactive 05)Study. J Am Coll Cardiol 49:1772-1780, 2007
PubMed
6) Wilcox R et al:Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke results from PROactive(PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38:865-873, 2007
 
7) Mazzone T et al:Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes:a randomized trial. JAMA 296:2572-, 2581, 2006
 
8) Nissen SE et al:Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes:the PERISCOPE randomized controlled trial. JAMA 299:1561-1573, 2008
PubMed
9) Lincoff AM et al:Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus:ameta-analysis of randomized trials. JAMA 298:1180-1188, 2007
 
10) Loke YK et al:Long-term use of thiazolidinediones and fractures in type 2 diabetes:a meta-analysis. CMAJ 180:32-39, 2009
PubMed
11) フランス保健製品衛生安全庁ホームページ :www. afssaps. fr/
 
12) Lewis JD et al:Risk of bladder cancer among diabetic patients treated with pioglitazone:interim report of a longitudinal cohort study. Diabetes Care 34:916-922, 2011
PubMed
13) Tseng CH:Pioglitazone and bladder cancer:a population-based study of Taiwanese. Diabetes Care 35:278-280, 2012
PubMed
14) Japan diabetes optimal integrated treatment study for 3 major risk factors of cardiovascular diseases(J-DOIT3)(clinicaltrials. gov/ct2/show/study/NCT00300976)
 
15) Yazaki Y et al:Combating diabetes and obesity in Japan. Nat Med 12:73-74, 2006.
PubMed
P.73 掲載の参考文献
1) Elrck H:Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 24:1076-1088, 1964
 
2) Nauck MA et al:Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492-498, 1986
 
3) 長嶋一昭, 稲垣暢也 :糖尿病学 基礎と臨床, 東京, 西村書店, 2007, pp.74-77
 
4) Seino Y et al:GIP and GLP-1, the two incretinhormones:similarities and difference. J Diabet lnvest 1:8-23, 2010
 
5) Ahren B et al:Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084, 2004
PubMed
6) Ahren B et al:Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with type 2 diabetes. J Clin Endcrinol Metab 94:1236-1243, 2009
 
7) Garber A et al:Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 Mono):a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 81:373-473, 2009
 
8) Mari A et al:Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessedβ-cell function in patients with type 2 diabetes. J Clin Endo Metab 90:4888-4894, 2005
 
9) Liu X et al:Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice. Life Sci 84:876-881, 2009
PubMed
10) de la Tour D et al:Beta-cell differentiation from a human pancreatic cell line in vitro and in vivo. Mol Endocrinol 15:476-483, 2001
PubMed
11) Farilla L et al:Gluccagon-kike peptide-1 promotes islet cell growth and inhibits in Zucker diabetic rats. Endocrinology 143:4397-4408, 2002
 
12) Hui H et al:Glucagon-like peptide-1 inhibit apoptosis of insuiin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A-and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144:1444-1455, 2003
 
13) Jhala US et al:cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 17:1494-1580, 2003
 
14) Mu J et al:Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704, 2006
 
15) Nonaka K et al:Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabet Res Clin Pract 9:291-298, 2008
 
16) Kikuchi M et al:Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 83:233-240, 2009
PubMed
17) Kawamori R et al:Linagliptin monotherapy improves glycemic control in Japanese patients with type 2 diabetes mellitus over 12 weeks. American Diabetes Association 70th Scientific Session. Abstract No 696-P
 
18) インタビューフォーム :シタグリプチン, MSD, 小野薬品
 
19) インタビューフォーム :ビルダグリプチン, ノバルティスファーマ
 
20) インタビューフォーム :アログリプチン, 武田薬品工業
 
21) 清野 裕 :2型糖尿病の病態と発症機構. 日本内科学会雑誌 93(9):1749-1760, 2004
 
22) Cho YM, Kieffer TJ:New aspects of an old drug:metformin as a glucagon-like peptide 1(GLP-1)enhancer and sensitiser. Diabetologia 54:219-222, 2011
PubMed
23) Narita T et al:Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 26:187-188, 2009
PubMed
24) Zhang CL et al:The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 325(5940):607-610, 2009
PubMed
25) Mukai E et al:Exendin-4 suppresses Src activation and reactive oxygen species production in diabetic GK rat islets in an Epac-dependent manner. Diabetes 60(1):218-226, 2011
 
26) Vardarli I et al:Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 96:945-954, 2011
PubMed
P.81 掲載の参考文献
1) La Barre JM:Sur les possibilitites d'un traitement du diabete par l'incretine. Bull Acad R Med Belg 12:620-634, 1932
 
2) Deacon CF et al:Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
PubMed
3) Meier JJ et al:Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53:654-662, 2004
PubMed
4) Nauck MA et al:Preserved incretin activity of glucagon-like peptide 1[7-36 amide]but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307, 1993
 
5) Agerso H et al:The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new longactive GLP-1 derivative, in healthy men. Diabetologia 45:195-202, 2002
 
6) Garber A et al(LEAD 3 Mono study group):Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 Mono):a randomized, 52-weeks, phase 3, double-blind, parallel-treatment trial. Lancet 373:473-481, 2009
 
7) Seino Y et al:Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain:A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 81(2):161-168, 2008
PubMed
8) Seino Y et al:Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 26:1013-1022, 2010
PubMed
9) Kaku K et al:Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 12:341-347, 2010
PubMed
10) Kadowaki T et al:Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 56(3):415-424, 2009
PubMed
P.86 掲載の参考文献
1) Maruyama T et al:Insulin intervention in slowly progressiveinsulin-dependent(type 1)diabetemellitus. J Clin Endocrinol Metab 93(6):2115-2121, 2008
 
2) United Kingdom Prospective Diabetes Study(UKPDS). 13:Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 14:310(6972):83-88, 1995
PubMed
3) 日本糖尿病学会編 :食事療法. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 東京, 南江堂, 2010, pp31-39
 
4) 日本糖尿病学会編 :運動療法. 糖尿病治療ガイド2010. 東京, 文光堂, 2010, pp42-44
 
5) 日本糖尿病学会編 :運動療法. 糖尿病専門医研修ガイドブック改訂第4版. 東京, 診断と治療社, 2009, pp97-106
 
6) Cauza E et al:The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus. Arch Phys Med Rehabil 86(8):1527-1533, 2005
PubMed
7) Riddle MC:Tactics for type II diabetes. Endocrinol Metab Clin North Am 26(3):659-677, 1997
PubMed
8) Riddle MC:Timely initiation of basal insulin. Am J Med 116(Suppl 3A):3S-9S, 2004
 
9) Nathan DM et al:Medical management of hyperglycemia in type 2 diabetes. Diabetes Care 29(8):1963-1972, 2006
PubMed
10) Fukushima M et al:Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 66(Suppl 1):S37-43, 2004
 
11) 谷川 敬一郎 :低血糖昏睡で搬送される糖尿病患者の増加について. 糖尿病 53(1):48, 2010
 
12) Amori RE et al:Efficacy and safety of incretin therapy in type 2 diabetes:systematic review and meta-analysis. JAMA 298(2):194-206, 2007
PubMed
13) Chiasson JL et al:STOP-NIDDM Trail Research Group:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial. Lancet 15:359(9323):2072-2077, 2002
 
14) Knowler WC et al:Diabetes prevention program research group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393-403, 2002
PubMed
15) Gerstein HC et al:Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:a randomised controlled triaL Lancet 368(9541):1096-1105, 2006
 
16) The NAVIGATOR study group:Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1463-1476, 2010
 
P.91 掲載の参考文献
1) Chiasson JL et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomized trial. Lancet 359(9323):2072-2077, 2002
PubMed
2) Kawamori R et al:Voglibose for prevention of type 2 diabetes mellitus:a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373(9675):1607-1614, 2009
PubMed
3) DECODE study group:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology:Collaborative analysis of Diagnostic criteria in Europe. Lancet 354(9179):617-621, 1999
 
4) Tominaga M et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The funagata diabetes study. Diabetes Care 22(6):920-924, 1999
 
5) Nauck MA et al:Preserved incretin activity of glucagon-like peptide 1[7-36 amide]but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91(1):301-307, 1993
 
6) Hojberg PV et al:Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with type 2 diabetes. Diabet Med 25(11):1268-1275, 2008
PubMed
7) UK Prospective Diabetes Study group:UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes:a progressive disease. Diabetes 44(11):1249-1258, 1995
 
8) DeFronzo RA et al:Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333(9):541-549, 1995
PubMed
9) UK Prospective Diabetes Study(UKPDS)group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet 352(9131):854-865, 1998
PubMed
10) Diabetes Prevention Program Research Group:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 346(6):393-403, 2002
 
11) Nathan DM et al:Medical management of hyperglycemia in type2 diabetes:a consensus algorithm for the initiation and adjustment of therapy:a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1):193-203, 2008
 
12) 加来浩平ほか :2型糖尿病治療におけるメトホルミン使用実態に関する観察研究 (More study). 糖尿病 49:325-331, 2006
 
13) Rosenstock J et al:Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 21(12):2050-2055, 1998
PubMed
14) Chiasson JL et al:The synergistic effect of miglitol plus metformin combination therapy in the treatment of type2 diabetes. Diabetes Care 24(6):989-994, 2001
 
15) Van Gaal L et al:Miglitol combined with metformin improves glycemic control in type 2 diabetes. Diabetes Obes Metab 3(5):326-331, 2001
 
16) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PRO spective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled triaL Lancet 366(9493):1279-1289, 2005
 
P.96 掲載の参考文献
1) U. K. Prospective Diabetes Study Group:U. K. prospective diabetes study 16. Overview of 6 Years' therapy of type II diabetes:A progressive disease. Diabetes 44:1249-1258, 1995
 
2) Funakoshi S et al:Analysis of factors influencing pancreatic β-cell function in Japanese patients with type 2 diabetes:association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract 82:353-358, 2008
 
3) Funakoshi S et al:Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. J Diabetes Invest 2(4):297-303, 2011
 
4) 「インクレチン(GLP-1受容体作動薬とDPP-4阻害薬)の適正使用に関する委員会」から:日本糖尿病学会 http://www. jds. or. jp/
 
5) Nagasaka S et al:Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabet Med 21:136-141, 2004
PubMed
6) Lecka-Czernik B:Bone loss in diabetes:use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 8:178-184, 2010
PubMed
7) ビクトーザ インタビューフォーム, ノボノルディスクファーマ社
 
P.101 掲載の参考文献
1) Nathan DM et al:Medical management of hyperglycemia in type 2 diabetes mellitus:a consensus algorithm for the initiation and adjustment of therapy:a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203, 2009
 
2) UKPDS:UK Prospective Diabetes Study(UKPDS)group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes[UKPDS34]. Lancet 352:854-865, 1998
PubMed
3) Turner RC et al:UK Prospective Diabetes Study(UKPDS)group:Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies[UKPDS49]. JAMA 281:2005-2012, 1999
PubMed
4) Belsey J et al:Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin and sulfonylurea:a meta-analysis. Diabetes Obes Metab 10:1-7, 2008
PubMed
5) Cook MN et al:Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 28:995-1000, 2005
PubMed
6) Evans JM et al:Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes:a comparison of patients with sulfonylureas and metformin. Diabetologia 49:930-936, 2006
PubMed
7) Holman RR et al:10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589, 2008
PubMed
8) Einhorn D et al:Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus:arandomized, placebo-controlled study. Clin Ther 22:1395-1409, 2000
 
9) Hamann A et al:Comparison of fixed-dose rosiglitazone/metformin combination theraphy with sulfonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes 116:6-13, 2008
 
10) Charbonnel B et al:Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 48:1093-1104, 2005
PubMed
11) Home PD et al:Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357:28-38, 2007
PubMed
12) Halimi S et al:Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin:a double-blind, placebo-controlled study. Diabetes Res Clin Pract 50:49-56, 2000
 
13) Phillips P et al:Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 26:269-273, 2003
PubMed
14) Moses R et al:Repaglinide in combination therapy with metformin in type 2 diabetes. Exp Clin Endocrinol Diabetes 107(Suppl 4):S136-139, 1999
 
15) Raskin P et al:Efficacy and safety of combination therapy:repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 26:2063-2068, 2003
PubMed
16) Thomas C et al:TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167-177, 2009
PubMed
17) Maida A et al:Metformin regulates the incretin receptor axis via a peroxisome proliferator-activated receptor alpha-dependent pathway in mice. Diabetologia 54:339-349, 2011
 
18) Scott R et al:Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 10:959-969, 2008
PubMed
19) Charbonnel B et al:Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29:2638-2643, 2006
PubMed
20) Ferrannini E et al:Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11:157-166, 2009
 
21) DeFronzo RA et al:Effects of exenatide(exendin-4)on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100, 2005
PubMed
22) Nauck M et al:Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes:the LEAD(liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90, 2009
PubMed
23) Altuntas Y et al:Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Diabetes Obes Metab 5:371-378, 2003
PubMed
24) Strowing SM et al:Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 25:1691-1698, 2002
 
25) 加来浩平ほか :2型糖尿病治療におけるメトホルミン使用実態に関する観察研究 (MORE study). 糖尿病 49:325-331, 2006
 
26) Ito H et al:Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus. Nutr Metab 7:83, 2010
PubMed
P.108 掲載の参考文献
1) Nathan DM et al:Medical management of hyperglycemia in type 2 diabetes:A consensus algorithm for the initiation and adjustment of therapy:A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203, 2009
 
2) Rodbard HW et al:Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus:An algorithm for glycemic control. Endocr Pract 15:540-559, 2009
 
3) 山崎勝也 :ビグアナイド薬の使い方. 小林 正編, 経口血糖降下薬の選び方と使い方. 東京, 南江堂, 2007, pp75-95
 
4) Zhou G et al:Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
PubMed
5) Johansen K:Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22:33-37, 1999
PubMed
6) ビグアナイド薬の適正使用に関する委員会 :ビグアナイド薬の適正使用に関するRecommendation. 日本糖尿病学会:http://www. jds. or. jp/jds_or_jp0/uploads/photos/830. pdf
 
7) 薄井 勲 :チアゾリジン薬の使い方. 小林 正編, 経口血糖降下薬の選び方と使い方. 東京, 南江堂, 2007, pp97-108
 
8) Okuno A et al:Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
PubMed
9) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):arandomised controlled trial. Lancet 366:1279-1289, 2005
PubMed
10) 山崎勝也ほか :メトホルミンとピオグリタゾン合剤の使い方. 月刊糖尿病 3:74-82, 2011
 
11) 岩田 実 :αグルコシダーゼ阻害薬の使い方. 小林 正編, 経口血糖降下薬の選び方と使い方. 東京, 南江堂, 2007, pp53-74
 
12) 浦風雅春 :スルホニル尿素薬の使い方. 小林 正編, 経口血糖降下薬の選び方と使い方. 東京, 南江堂, 2007, pp27-43
 
13) 原島伸一ほか :糖尿病治療薬の進歩:インクレチン関連薬. MEDICINAL 1:64-71, 2011
 
P.118 掲載の参考文献
1) Haffner SM et al:Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
PubMed
2) Gaede P et al:Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
PubMed
3) Action to Control Cardiovascular Risk in Diabetes Study Group:Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559, 2008
 
4) ADVANCE Collaborative Group:Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572, 2008
 
5) 柏木厚典 :糖尿病大血管症の概念と病態生理学的特徴. 日本臨床 68(5):777-787, 2010
Medical*Online
6) Sekine O et al:Insulin activates CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. J Biol Chem 277:36631-36639, 2002
 
7) Sato Y et al:Increased expression of CCAAT/enhancer binding protein beta and delta and monocyte chemoattractant protein-1 genes in aortas from hyperinsulinaemic rats. Diabetologia 50:481-489, 2007
PubMed
8) The DECODE study group:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes Epidemiology:Collaborative analysis of Diagnostic criteria in Europe. Lancet 354:617-621, 1999
 
9) Tominaga M et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
 
10) STOP-NIDDM Trial Research Group:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial. JAMA 290:486-494, 2003
 
11) Hanefeld M et al:Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:meta- analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
PubMed
12) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study(PROspective pioglitAzone Clinical Trial In macroVascular Events):arandomized controlled trial. Lancet 366:1279-1289, 2005
 
13) Wilcox R et al:Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke:results from PROactive(PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38:865-873, 2007
 
14) Mazzone T et al:Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes:arandomized trial. JAMA 296:2572-2581, 2006
 
15) Nissen SE et al:PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes:the PERISCOPE randomized controlled trial. JAMA 299:1561-1573, 2008
PubMed
16) UK Prospective Diabetes Study(UKPDS)group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet 352:854- 865, 1998
 
17) Roussel R et al:Reduction of Atherothrombosis for Continued Health(REACH)Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170:1892-1899, 2010
PubMed
18) NAVIGATOR Study Group, Holman RR et al:Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1463-1476, 2010
 
19) UK Prospective Diabetes Study(UKPDS)Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
 
20) Holman RR et al:10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589, 2008
PubMed
21) McGuire DK et al:Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 147:246-252, 2004
PubMed
P.126 掲載の参考文献
1) Cockcroft DW et al:Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
PubMed
2) Levey AS et al:Amore accurate method to estimate glomerular filtration rate from serum creatinine:A new prediction equation. Ann Intern Med 130:461-470, 1999
 
3) Matsuo S et al:Revised equation for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982-992, 2009
PubMed
4) Levey AS et al:The definition, classification, and prognosis of chronic kidney disease:a KDIGO Controversies Conference report. Kidney Int 80:17-28, 2011
PubMed
5) 羽田勝計 :腎機能低下を考慮した糖尿病治療戦略. 新薬と臨床 60:2386-2395, 2011
Medical*Online
6) Haneda M Morikawa A:Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?Nephrol Dial Transplant 24:338-341, 2009
PubMed
P.135 掲載の参考文献
1) The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus:The Diabetes Control and Complications TriaL Arch Ophthalmol 113:36-51, 1995
PubMed
2) UKPDS Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). UK Prospective Diabetes Study. Lancet 352:837-853, 1998
 
3) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874-886, 1998
PubMed
4) The Kroc Collaborative Study Group:Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial N Engl J Med 311:365-372, 1984
 
5) Lauritzen T et al:Effect of 1 year of near-normal blood glucose levels on retinopathy in insulindependent diabetics. Lancet 1:200-204, 1983
PubMed
6) Funatsu H et al:Effect of rapid glycemic control on progression of diabetic retinopathy. Jpn J Ophthalmol 36:356-367, 1992
PubMed
7) Rosenstock J et al:Basal insulin therapy in type 2 diabetes:28-week comparison of insulin glargine (HOE 901)and NPH insulin. Diabetes Care 24:631-636, 2001
PubMed
8) Lu M et al:Insulin-induced vascular endothelial growth factor expression in retina. Invest Ophthalmol Vis Sci 40:3281-3286, 1999
PubMed
9) Poulaki V et al:Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest 109:805-815, 2002
PubMed
10) Shen LQ et al:Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol 126:793-799, 2008
PubMed
11) Fong DS, Contreras R:Glitazone use associated with diabetic macular edema. Am J Ophthalmol 147:583-586, 2009
PubMed
12) Ambrosius WT et al:ACCORD Study Group:Lack of association between thiazolidinediones and macular edema in type 2 diabetes:the ACCORD eye substudy. Arch Ophthalmol 128:312-318, 2010
 
13) Nagi DK, Yudkin JS:Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 16:621-629, 1993
PubMed
14) Xavier DO et al:Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed Pharmacother 64:220-225, 2010
 
15) UK Prospective Diabetes Study Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 317:703-713, 1998
Medical*Online
16) ACCORD Study Group:Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363(3):233-244, 2010
 
17) ACCORD Study Group:Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362(17):1575-1585, 2010
 
18) Mauer M et al:Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:40-51, 2009
PubMed
19) Chaturvedi N et al:Effect of candesartan on prevention(DIRECT-Prevent 1)and progression(DIRECT-Protect 1)of retinopathy in type 1 diabetes:randomized placebo-controlled trials. Lancet 372:1394-1402, 2008
PubMed
20) Sjolie AK et al:Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2):a randomised placebo-controlled trial. Lancet 372:1385-1393, 2008
PubMed
21) Chew EY et al:Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study(ETDRS)report 22. Arch Ophthalmol 114:1079-1084, 1996
PubMed
22) Colhoun HM et al:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS):multicentre randomised placebo-controlled triaL Lancet 364:685-696, 2004
PubMed
23) Gaede P et al:Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
PubMed
24) Lyons TJ et al:Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest. Ophthalmol Vis Sci 45:910-918, 2004
PubMed
25) Duncan LJ et al:A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 17:458-467, 1968
PubMed
26) Cullen JF et al:Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK 94:554-562, 197
 
27) Cullen JF et al:A controlled trial of Atromid therapy in exudative diabetic retinopathy. Trans Ophthalmol Soc UK 84:281-295, 1964
PubMed
28) Keech AC et al;FIELD study investigators:Effect of fenofibrate on the need for laser treatment for diabetic retinopathy(FIELD study):a randomised controlled trial. Lancet 370(9600):1687-1697, 2007
 
29) The DAMAD Study Group:Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 38:491-498, 1989
 
30) The TIMAD Study Group:Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 108:1577-1583, 1990
 
31) Phipps JA et al:Plasma kallikrein mediates angiotensin II type I receptor-stimulated retinal vascular permeability. Hypertension 53:175-181, 2009
PubMed
32) Yoshida T et al:Digoxin inhibits retinal ischemia-induced HIF-1α expression and ocular neovascularization. FASEB J 24(6):1759-1767, 2010
 
33) Tong Z et al:Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA 105:6998-7003, 2008
PubMed
P.142 掲載の参考文献
1) Noda Y et al:Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals:an ESR study. Res Commun Mol Pathol Pharmacol 96:115-124, 1997
PubMed
2) Ceriello A:Effects of gliclazide beyond metabolic control. Metabolism 55:S10-S15, 2006
PubMed
3) Qiang X et al:Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats. Metabolism 47:977-981, 1998
PubMed
4) Kitahara Y et al:Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes. Metabolism 51:1452-1457, 2002
PubMed
5) Hara T et al:An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibitor in NIDDM. Diabetes Care 19:642-647, 1996
 
6) Wile D et al:Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 33:156-161, 2010
PubMed
7) Tanaka Y et al:Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats. Eur J Pharmacol 376:17-22, 1999
PubMed
8) Ota K et al:Metformin prevents methyglyoxal-induced apoptosis of mouse Schwann cells. Biochem Biophys Res Commun 357:270-275, 2007
 
9) Yamagishi S et al:Correction of protein kinace C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats. J Neurochem 104:491-499, 2008
 
10) Wiggin TD et al:Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin. treated DBA/2J mice. Endocrinology 149:4928-4937, 2008
PubMed
11) Perry T et al:A novel neurotrophic property of glucagon-like peptide 1:a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300:958-966, 2002
 
12) Perry T et al:Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 203:293-301, 2007
 
13) Buhren BA et al:Glucose-dependent insulinotropic polypeptide(GIP)and its receptor(GIPR):cellular localization, lesion-affected expression, and impaired regenerative axonal growth. J Neurosci Res 87:1858-1870, 2009
PubMed
14) Himeno T et al:Beneficial effects of exendin-40n experimental polyneuropathy in diabetic mice. Diabetes 60:2397-2406, 2011
 
15) Jin HY et al:Effect of dipeptidyl peptidase-IV(DPP-IV)inhibitor(Vildagliptin)on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res 40:536-544, 2009.
PubMed
P.150 掲載の参考文献
1) 科学的根拠に基づく糖尿病診療ガイドライン策定に関する委員会 :経口薬による治療 (インスリンを除く), 日本糖尿病学会編, 科学的根拠に基づく糖尿病診療ガイドライン 2010, 東京, 南江堂, 2010, pp51-63
 
2) 科学的根拠に基づく糖尿病診療ガイドライン策定に関する委員会 :糖尿病診療ガイドライン策定作業の方法論, 日本糖尿病学会編, 科学的根拠に基づく糖尿病診療ガイドライン 2010, 東京, 南江堂, 2010, pp1-5
 
3) 科学的根拠に基づく糖尿病診療ガイドライン策定に関する委員会 :高齢者の糖尿病, 日本糖尿病学会編, 科学的根拠に基づく糖尿病診療ガイドライン 2010, 東京, 南江堂, 2010, pp219-230
 
4) Ismail-Beigi F et al:Individualizing glycemic targets in type 2 diabetes mellitus:Implications of recent clinical trials. Ann Intern Med 154:554-559, 2011
PubMed
5) 日本老年医学会 :高齢者で重視すべき慢性疾患管理の要点, 健康長寿ハンドブック -実地医家のための老年医学のエッセンス- 日本老年医学会編, 第1版, 東京, メジカルビュー, 2011, pp37-47
 
6) Brown AF et al:Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 51:S265-280, 2003
PubMed
7) Pogach LM et al:Development of evidence-based clinical practice guidelines for diabetes. Diabetes Care 27(Suppl 2):B82-B89, 2004
 
8) Paolisso G:Pathophysiology of diabetes in elderly people. Acta Biomed 81(Suppl 1):47-53, 2010
 
9) Whitmer RA et al:Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301:1565-1572, 2009
PubMed
10) Monnier L et al:Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients:Variations with increasing levels of HbA1c. Diabetes Care 26:881-885, 2003
 
11) Neumiller JJ et al:Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother 7:324-342, 2009
PubMed
12) インクレチン(GLP-1受容体作動薬とDPP-4阻害薬)の適正使用に関する委員会:http://www. jds. or. jp/jds_or_jp0/uploads/photos/797. pdf
 
13) Nathan DM et al:Medical management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initiation and adjustment of therapy:a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203, 2009
 
14) Landman GW et al:Metformin associated with lower cancer mortality in type 2 diabetes:ZODIAC-16. Diabetes Care 33:322-326, 2010
PubMed
15) 横野浩一, 中野忠澄:高齢者糖尿病 -最新事情- . Online DITN 404 http://novonordisk. co. jp/DITN/2011/ditn1111. pdf#
 

3. トピックス

P.158 掲載の参考文献
1) Miki T et al:The structure and function of the ATP-sensitive K+channel in insulin-secreting pancreatic beta-cells. J Mol Endocrinol 22(2):113-123, 1999
PubMed
2) Zhang CL et al:The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 325:607-610, 2009
PubMed
3) Shibaksaki T et al:Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci USA 104:19333-19338, 2007
 
4) Seino S et al:Sulfonylurea action re-revised. J Diabetes Invest 1:37-39, 2010
 
5) Kominato R et al:Src activation generates reactive oxygen species and impairs metabolism-secretion coupling in diabetic Goto-Kakizaki and ouabain-treated rat pancreatic islets. Diabetologia 51:1226-1235, 2008
PubMed
6) Mukai E et al:Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an epac-dependent manner. Diabetes 60:218-226, 2011
 
7) Mukai E et al:Metabolic inhibition impairs ATP-sensitive K+channel block by sulfonylurea in pancreatic beta-cells. Am J Physiol 274:E38-E44, 1998
PubMed
8) de Heer J et al:Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 56:438-443, 2007
PubMed
9) 日本糖尿病学会ホームページ :http://www. jds. or. jp/
 
P.163 掲載の参考文献
2) Nonaka K et al:Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 79:291-298, 2008
PubMed
3) Aoki K et al:Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 57(8):667-672, 2010
 
4) 加来浩平ほか:2型糖尿病患者におけるメトホルミンの使用実態に関する観察研究 (MORE study). 糖尿病 49:325-331, 2006
 
5) Lindsay JR et al:Inhibition of dipeptidyl peptidase 4 activity by oral metformin in type 2 diabetes. Diabet Med 22:654-657, 2005
PubMed
6) Migoya EM et al:Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 88:801-808, 2010
 
7) Katsuma S et al:Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329:386-390, 2005
 
8) Kadowaki T et al:Sitagliptin added to ongoing treatment with metformin improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes. ADA 68th poster session, 2008
 
9) Raz l et al:Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 24:537-550, 2008
 
10) Williams-Herman D et al:Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 12:442-451, 2010
PubMed
P.169 掲載の参考文献
1) リラグルチド (遺伝子組換え) 安全情報 (ブルーレター 2010年10月)
 
2) 「インクレチン (GLP-1受容体作動薬とDPP-4阻害薬) の適正使用に関する委員会」による勧告 http://www. jds. or. jp/jds_or_jp0/uploads/photos/797. pdf
 
P.173 掲載の参考文献
1) Kahn SE et al:Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006
 
2) Kahn SE et al:Rosiglitazone-associated fractures in type 2 diabetes:an Analysis from A Diabetes Outcome Progression Trial(ADOPT). Diabetes Care 31:845-851, 2008
PubMed
3) Home PD et al:Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes(RECORD):a multicentre, randomised, open-label trial. Lancet 373:2125-2135, 2009
PubMed
4) Dormandy J et al:Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes:an overview of data from PROactive. Drug Saf 32:187~202, 2009
 
5) Nissen SE et al:Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes:the PERISCOPE randomized controlled trial. JAMA 299:1561-1573, 2008
PubMed
6) Loke YK et al:Long-term use of thiazolidinediones and fractures in type 2 diabetes:ameta-analysis. CMAJ 180:32-39, 2009
 
7) Douglas IJ et al:The risk of fractures associated with thiazolidinediones:aself-controlled case-series study. PLoS Med 6:e1000154, 2009
 
8) Lecka-Czernik B:Bone loss in diabetes:use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos 8:178-184, 2010
PubMed
P.180 掲載の参考文献
1) Urabe T et al:Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke 40:1289-1295, 2009
PubMed
2) 河盛隆造:糖のながれにおける肝・糖取り込み率制御因子の解明. 糖尿病 49:771-773, 2006
 
3) Chiasson JL et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
PubMed
4) Chiasson JL et al:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial. JAMA 290:486-494, 2003
PubMed
5) Kawamori R et al:Voglibose for prevention of type 2 diabetes mellitus:a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373:1607-1614, 2009
PubMed
6) Scheen AJ:Voglibose for prevention of type 2 diabetes mellitus. Lancet 373:1579-1580, 2009
PubMed
7) Hanefeld M et al:Risk factors for myocardial infarction and death in newly detected NIDDM:the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
PubMed
8) Hanefeld M et al:Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
PubMed
9) The NAVIGATOR Study Group:Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med published on line 2010
 
10) Li G et al:The long-term effect of lifestyle interventions to prevent diabetes in the china Da Qing Diabetes Prevention Study:a 20-year follow-up study. Lancet 371:1783-1789, 2008
 
11) Arakawa M et al:Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 57:1299-1306, 2008
PubMed
12) Arakawa M et al:Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59:1030-1037, 2010
PubMed
P.184 掲載の参考文献
1) UK Prospective Diabetes Study(UKPDS)group:Effect of intensive blood-glucose control with metforminon complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet 352(9131):854-865, 1998
 
2) 加来浩平ほか:2型糖尿病治療におけるメトホルミンの使用実態に関する観察研究 (MORE study) 糖尿病 49:325-331, 2006
 
3) Bennett WL et al:Comparative effectiveness and safety of medications for type 2 diabetes:an update including new drugs and 2-drug combinations. Ann Intern Med 154(9):602-613, 2011
PubMed
4) 大日本住友製薬 :メトグルコ(R)錠250mg添付文書 2011年6月改訂 (第2版)
 
P.189 掲載の参考文献
1) 医薬品インタビューフォーム873969. 2011年9月第9版 pp14-41.
 
2) 原島伸一ほか:Sitagliptin B Study:BOTからシタグリプチンへの切替え症例の検討. 第54回日本糖尿病学会年次学術集会, 札幌, 2011
 
3) 日本糖尿病学会:インクレチン(GLP-1受容体作動薬とDPP-4阻害薬)の適正使用に関する委員会. http://www. jds. or. jp/jds_or_jp0/uploads/photos/625. pdf
 

書評

最近チェックした商品履歴

Loading...